Although long-term protection is a key-point in evaluating HPV-vaccine over time, there is
currently inadequate information on the duration of HPV vaccine-induced immunity and on …

Background. Baseline information on human papillomavirus (HPV) prevalence and type
distribution is highly desirable to evaluate the impact of prophylactic HPV vaccines in the …

Background The natural history of human papillomavirus (HPV) infections in older women is
critical for preventive strategies, including vaccination and screening intervals, but is poorly …

Objective: The goal of this cross-sectional laboratory-based study is to investigate the
association between Trichomonas vaginalis (TV) and human papillomavirus (HPV) …

We report efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3
years post-vaccination. The study was conducted in a population (N= 433) of women …

There is a paucity of data on whether or not women can be reinfected with human
papillomavirus (HPV) types to which they were exposed to earlier in life and on the role of …

Background Benign or malignant lesions caused by Human papillomavirus (HPV) produce
considerable health burden worldwide. Since limited cross-protection would be offered …

Background: Cervical human papilloma virus (HPV) detection increases after menopause,
but its determinants need clarification. Methods: In a case–control study nested within a …

Persisting human papillomavirus (HPV) infection is a critical step in cervical carcinogenesis.
This study was conducted to determine the type‐specific HPV persistence and risk factors for …

Objectives Cervical cancer is the most common malignancy among Nepalese women.
Rational prevention measures are informed by epidemiological data on human …